GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner
GlaxoSmithKline (GSK) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, GlaxoSmithKline rose 31 cents (0.7%) to $46.51 on average volume. Throughout the day, 2.3 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock ranged in a price between $46.17-$46.59 after having opened the day at $46.44 as compared to the previous trading day's close of $46.20. Other companies within the Health Care sector that increased today were: Arena Pharmaceuticals (ARNA), up 21.9%, Abaxis (ABAX), up 20.9%, IVAX Diagnostics (IVD), up 15.5%, and Jazz Pharmaceuticals (JAZZ), up 14.4%. GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $116.13 billion and is part of the drugs industry. The company has a P/E ratio of 13.9, below the average drugs industry P/E ratio of 14.3 and below the S&P 500 P/E ratio of 17.7. Shares are up 1.2% year to date as of the close of trading on Thursday. Currently there are five analysts that rate GlaxoSmithKline a buy, no analysts rate it a sell, and three rate it a hold. TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated.
- You can view the full GlaxoSmithKline Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Latest Headlines about GSK
-
Cramer's 'Mad Money' Recap: Ignore the Fed
07:45PM 05/22/13
-
Toll Reports Better-than-Expected Earnings: Ahead of the Ticker
09:55AM 05/22/13
-
2013 FDA Drug Approval Calendar
07:00AM 05/21/13
-
Aveo Screwed Up but Its Kidney Cancer Drug Is Real
09:24AM 05/15/13
-
Buffett's Long-Term, High-Dividend Plays
03:45AM 05/04/13
-
Aveo's Kidney Cancer Drug Won't Get FDA Panel OK
10:10AM 04/25/13
-
Amarin's Fish Oil Pill Faces Even More Exclusivity Risks
09:35AM 04/22/13
Latest from TheStreet Wire
-
Avago Technologies Ltd (AVGO): Today's Featured Electronics Laggard
05:01PM 05/23/13
-
Wynn Resorts Ltd (WYNN): Today's Featured Services Laggard
05:01PM 05/23/13
-
Pentair Ltd (PNR): Today's Featured Industrial Laggard
05:01PM 05/23/13
-
Microsoft Corporation (MSFT): Today's Featured Computer Software & Services Laggard
05:01PM 05/23/13
-
Michael Kors Holdings Ltd (KORS): Today's Featured Retail Laggard
05:01PM 05/23/13
-
Devon Energy Corp (DVN): Today's Featured Basic Materials Laggard
05:01PM 05/23/13
-
Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard
05:01PM 05/23/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
